# A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

> **NCT07071337** · PHASE3 · RECRUITING · sponsor: **Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.** · enrollment: 430 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** SKB264
- **DRUG:** Nab-paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07071337
- **Lead sponsor:** Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-18
- **Primary completion:** 2027-07
- **Final completion:** 2031-02
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07071337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07071337, "A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT07071337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*